Simon Tian

Simon Tian

Vertex Pharmaceuticals - Boston / United States
Others
AD Scientific Index ID: 4615858
-
person_outline Simon Tian's MOST POPULAR ARTICLES
1-) Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allelePG Middleton, MA Mall, P Dřevínek, LC Lands, EF McKone, D Polineni, ...New England Journal of Medicine 381 (19), 1809-1819, 20199532019
2-) Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trialF Ratjen, C Hug, G Marigowda, S Tian, X Huang, S Stanojevic, CE Milla, ...The Lancet Respiratory Medicine 5 (7), 557-567, 20172632017
3-) Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR …MW Konstan, EF McKone, RB Moss, G Marigowda, S Tian, D Waltz, ...The lancet Respiratory medicine 5 (2), 107-118, 20172572017
4-) Ivacaftor treatment of cystic fibrosis in children aged 12 to< 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyM Rosenfeld, CE Wainwright, M Higgins, LT Wang, C McKee, D Campbell, ...The lancet respiratory medicine 6 (7), 545-553, 20182612018
5-) Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registriesN Volkova, K Moy, J Evans, D Campbell, S Tian, C Simard, M Higgins, ...Journal of Cystic Fibrosis 19 (1), 68-79, 20202522020